Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.72 |
| ▸ | DRD3 | P35462 | 9/20 | 0.72 |
| ▸ | DRD4 | P21917 | 5/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | HTR1A | P08908 | 2/20 | 0.72 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CASP1 | P29466 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | FYN | P06241 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8689191 | 0.87 | DRD3 (0.66) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL29448457 | 0.84 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL7449296 | 0.84 | DRD2 (0.70) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL29460204 | 0.84 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL8930123 | 0.84 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL623950 | 0.84 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL7568447 | 0.84 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL7411429 | 0.84 | DRD2 (0.70) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL6558764 | 0.84 | DRD2 (0.70) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL7411424 | 0.84 | DRD2 (0.70) | DRD2DRD3DRD4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160015684-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SPRIASO LLC | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015684-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SLC7A1, CYP2D6, CYP3A7 | DRD2 1602/4885DRD3 1564/4885DRD4 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.